Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis

Simple item page
dc.contributor.authorBardhan K.D.
dc.contributor.authorVan Rensburg C.
dc.date.accessioned2011-05-15T16:15:17Z
dc.date.available2011-05-15T16:15:17Z
dc.date.issued2001
dc.description.abstractBackground: Several clinical trials have shown that pantoprazole (40 mg) and omeprazole (40 or 20 mg) have similar efficacy and safety in the treatment of grade II-IV reflux oesophagitis (Savary-Miller classification). Aim: To compare the efficacy and safety of once-daily doses of pantoprazole (20 rog) and omeprazole (20 mg) with respect to symptom relief and healing of patients with grade I reflux oesophagitis. Methods: Patients with endoscopically established grade I reflux oesophagitis (non-confluent, patchy red lesions with/without white fibrin coating) were enrolled into this randomized, open, parallel-group, multicentre study. A total of 328 patients (n = 166 in the pantoprazole group, n = 162 in the omeprazole group) were recruited in 23 centres. Patients received 4 weeks of treatment. If the reflux oesophagitis was not completely healed, the treatment was extended to 8 weeks. Results: After 2 and 4 weeks of treatment with either pantoprazole or omeprazole, the rate of symptom relief was similar (70% vs. 79% and 77% vs, 84%, respectively). High healing rates were observed after 4 and 8 weeks (pantoprazole: 84% and 90%, respectively; omeprazole: 89% and 95%, respectively). Both treatments were well tolerated. The most frequently reported adverse events on pantoprazole and omeprazole, respectively, were nausea (8% vs. 7%), diarrhoea (5% vs. 6%) and headache (6% vs. 3%). Conclusions: After 4 and 8 weeks of treatment with pantoprazole (20 mg) or omeprazole (20 mg), patients with mild gastro-oesophageal reflux disease (grade I) showed comparably high rates of symptom relief and healing. Both treatments were safe and well tolerated.
dc.description.versionArticle
dc.identifier.citationAlimentary Pharmacology and Therapeutics
dc.identifier.citation15
dc.identifier.citation10
dc.identifier.issn02692813
dc.identifier.other10.1046/j.1365-2036.2001.01089.x
dc.identifier.urihttp://hdl.handle.net/10019.1/13273
dc.subjectomeprazole
dc.subjectpantoprazole
dc.subjectadult
dc.subjectarticle
dc.subjectclinical trial
dc.subjectcomparative study
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdiarrhea
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdrug tolerability
dc.subjectfemale
dc.subjectheadache
dc.subjecthealing
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmulticenter study
dc.subjectnausea
dc.subjectpriority journal
dc.subjectrandomized controlled trial
dc.subjectreflux esophagitis
dc.subjectsymptomatology
dc.subject2-Pyridinylmethylsulfinylbenzimidazoles
dc.subjectAdult
dc.subjectAnti-Ulcer Agents
dc.subjectBenzimidazoles
dc.subjectEsophagitis, Peptic
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectOmeprazole
dc.subjectSulfoxides
dc.subjectTreatment Outcome
dc.titleComparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications